Consensus Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
9.31 USD -2.62% Intraday chart for Voyager Therapeutics, Inc. -0.96% +10.31%

Evolution of the average Target Price on Voyager Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

41dcaefff3b5.y_7TsnJioPff9YGRbxy-0NgeOJjXRRYnDTJB4L0CFYs.rs2Q_BQB4s6ppPH_DEuG5r4mCszmFmwVb305jpA2SuiFuqX4OhX3s7mltQ~07ea8255c4df2ead6367f9edc2dbfb89
Guggenheim Initiates Voyager Therapeutics With Buy Rating, $22 Price Target MT
H.C. Wainwright Initiates Coverage on Voyager Therapeutics With Buy Rating, $30 Price Target MT
Citigroup Starts Voyager Therapeutics With Buy Rating, $16 Price Target MT
Wedbush Trims Voyager Therapeutics' Price Target to $10 From $11, Neutral Rating Kept MT
US job data raises doubts about the Fed's next moves Our Logo
Wedbush Lifts Voyager Therapeutics' PT to $11 From $10, Says New Agreement With Novartis Unit Generate More Non-Dilutive Capital To Start Year; Keeps Neutral Rating MT
Truist Starts Voyager Therapeutics at Buy With $18 MT
Oppenheimer Initiates Coverage on Voyager Therapeutics With Outperform Rating, $14 Price Target MT
Wedbush Raises Voyager Therapeutics' Price Target to $10 From $4, Keeps Neutral Rating MT
Wedbush Adjusts Voyager Therapeutics Price Target to $4 From $3, Maintains Neutral Rating MT
Wedbush Cuts Price Target on Voyager Therapeutics to $3 From $4 on 'Lower Net Cash,' Maintains Neutral Rating MT
Chardan Research Adjusts Price Target on Voyager Therapeutics to $6 From $4; Neutral Rating Kept MT
Wedbush Adjusts Voyager Therapeutics Price Target to $4 From $3, Maintains Neutral Rating MT
Chardan Adjusts Price Target on Voyager Therapeutics to $4 From $5.50 While Awaiting Info on New Pipeline, Maintains Neutral Rating MT
VOYAGER THERAPEUTICS : Baird Upgrades Voyager Therapeutics to Outperform from Neutral, Adjusts Price Target to $9 from $6 MT
VOYAGER THERAPEUTICS : Wedbush Adjusts Voyager Therapeutics' PT to $3 From $6, Citing Profit Share Arrangement, Potential Secondary Offering Size; Neutral Rating Kept MT
VOYAGER THERAPEUTICS : Baird Downgrades Voyager Therapeutics to Neutral From Outperform, Adjusts Price Target to $6 From $18 MT
Chardan Adjusts Price Target on Voyager Therapeutics to $6.50 From $15, Maintains Neutral Rating MT
VOYAGER THERAPEUTICS : Chardan Adjusts Price Target on Voyager Therapeutics to $6.50 From $15, Maintains Neutral Rating MT
VOYAGER THERAPEUTICS : Morgan Stanley Adjusts Price Target on Voyager Therapeutics to $7 From $13, Keeps Equal-Weight Rating MT
VOYAGER THERAPEUTICS : BTIG Downgrades Voyager Therapeutics to Neutral From Buy MT
VOYAGER THERAPEUTICS : Wedbush Cuts Voyager Therapeutics to Neutral From Outperform, PT to $6 From $13 as Neurocrine Biosciences Ends Gene Therapy Collaboration MT
VOYAGER THERAPEUTICS : Cantor Fitzgerald Downgrades Voyager Therapeutics to Neutral From Overweight, Adjusts Price Target to $10 From $15 MT
VOYAGER THERAPEUTICS : Raymond James Downgrades Voyager Therapeutics to Market Perform From Outperform MT
VOYAGER THERAPEUTICS : BTIG Adjusts Price Target on Voyager Therapeutics to $18 From $31, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.31 USD
Average target price
17.78 USD
Spread / Average Target
+90.95%
High Price Target
30 USD
Spread / Highest target
+222.23%
Low Price Target
10 USD
Spread / Lowest Target
+7.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Voyager Therapeutics, Inc.

Guggenheim
HC Wainwright
Citigroup
Wedbush
Truist Securities
Oppenheimer
Chardan Research
Chardan
Baird
BTIG
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings